A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms CheckMate140
- Sponsors Bristol-Myers Squibb
- 13 Mar 2018 This trial has been completed in Spain.
- 17 Feb 2018 This trial has been discontinued in Sweden, according to European Clinical Trials Database record.
- 31 May 2017 Planned End Date changed from 24 Jan 2018 to 24 Jul 2018.